Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed an 8-K current report with the SEC on April 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Four PEDMARK abstracts accepted for presentation or publication at the 2026 ASCO Annual Meeting.
FENNEC PHARMACEUTICALS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Four PEDMARK abstracts accepted for presentation or publication at the 2026 ASCO Annual Meeting
- ASCO exposure provides additional visibility for PEDMARK among oncology specialists and potential prescribers
- Scientific details and data are contained in Exhibit 99.1, including any implications for clinical adoption
Item EX-99.1 · Exhibit EX-99.1
- Four PEDMARK studies accepted at 2026 ASCO, increasing visibility for Fennec’s ototoxicity-prevention franchise
- Presentations include pediatric, adolescent, young-adult, and adult cisplatin-treated populations, supporting potential market expansion
- Two abstracts provide real-world and audiometric evidence beyond PEDMARK’s current pediatric indication
- Full abstracts available May 21, ahead of ASCO’s May 29-June 2 meeting
- Key investor catalyst: clinical data could influence physician adoption and future label or guideline expansion beyond pediatric localized tumors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FENNEC PHARMACEUTICALS INC. 8-K filings
Get the next FENC 8-K as it lands
Follow FENC for push alerts, or ask the research agent what this filing means.